723 results on '"Kumar, Alan Prem"'
Search Results
2. The emerging role of human papillomavirus in lung cancer
3. Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy
4. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
5. Phytostilbenes in lymphoma: Focuses on the mechanistic and clinical prospects of resveratrol, pterostilbene, piceatannol, and pinosylvin
6. Exosomal long non-coding RNAs (lncRNAs) in cancer progression and diagnosis
7. Delineating the role of nuclear receptors in colorectal cancer, a focused review
8. CXCR4 expression is elevated in TNBC patient derived samples and Z-guggulsterone abrogates tumor progression by targeting CXCL12/CXCR4 signaling axis in preclinical breast cancer model
9. Modulation of epigenetic methylation enzymes by synthetic and natural agents
10. Contributors
11. Loganic acid regulates the transition between epithelial and mesenchymal-like phenotypes by alleviating MnSOD expression in hepatocellular carcinoma cells
12. Potential Application of Natural Compounds for the Prevention and Treatment of Hepatocellular Carcinoma
13. Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer
14. Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer
15. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
16. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
17. The long and short non-coding RNAs modulating EZH2 signaling in cancer
18. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response
19. Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches
20. Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology
21. Differences between multimodal brain-age and chronological-age are linked to telomere shortening
22. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy
23. Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator?
24. Daidzin targets epithelial-to-mesenchymal transition process by attenuating manganese superoxide dismutase expression and PI3K/Akt/mTOR activation in tumor cells
25. Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies
26. Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression
27. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities
28. Mindfulness intervention for mild cognitive impairment led to attention-related improvements and neuroplastic changes: Results from a 9-month randomized control trial
29. The functional and structural connectomes of telomere length and their association with cognition in mild cognitive impairment
30. Novel amide analogues of quinazoline carboxylate display selective antiproliferative activity and potent EGFR inhibition
31. Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers
32. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers
33. Role of histone acetyltransferase inhibitors in cancer therapy
34. Role of NF-κB Activation in Multiple Myeloma and Other Hematological Malignancies
35. Macrophage IL-1β contributes to tumorigenesis through paracrine AIM2 inflammasome activation in the tumor microenvironment
36. Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases
37. Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma
38. Supplementary Table S1 and Figures S1-6 from Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
39. Data from Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
40. Supplementary Methods from Repression of NHE1 Expression by PPARγ Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo
41. Supplementary Figures 1-6 from Repression of NHE1 Expression by PPARγ Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo
42. Supplementary Figure Legends 1-6 from Repression of NHE1 Expression by PPARγ Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo
43. Supplementary Table 1 from Repression of NHE1 Expression by PPARγ Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo
44. Data from Repression of NHE1 Expression by PPARγ Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo
45. Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response
46. Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds
47. Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy
48. Author Correction: c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression
49. c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression
50. Contributors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.